Clinical Trial

Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.

Study acronym: CASTLE-ZS-03
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of cryoablation combined with SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, plus famitinib, a multi-targeted receptor tyrosine kinase inhibitor, in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.
Trial Details
NCT Number NCT07147088
Lead Sponsor Fudan University
Conditions Advanced Intrahepatic Cholangiocarcinoma
Enrollment 36 participants
Start Date 2025-09-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-28